GTBP
GT Biopharma, Inc.
Price Chart
Latest Quote
$0.49
-0.00 (-0.77%)
Current Price
| Previous Close | $0.49 |
| Open | $0.51 |
| Day High | $0.51 |
| Day Low | $0.48 |
| Volume | 217,152 |
Stock Information
| Shares Outstanding | 36.06M |
| Cash Equivalents | $8.92M |
| Net Income | $-37.04M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $17.67M |
| EPS (TTM) | $-6.46 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.89M |
| Income | $-37.04M |
| Book/sh | $0.21 |
| Cash/sh | $0.25 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 3.69 |
| Current Ratio | 4.14 |
Returns & Margins
| ROA | -131.76% |
| ROE | -921.55% |
Ownership
| Insider Ownership | 3.42% |
| Institutional Ownership | 6.93% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.05 |
| PEG | 1.05 |
| P/B | 2.28 |
Analyst Data
| Recommendation | none |
| Target Price | $3.00 |
Technical Indicators
| SMA20 | $0.45 |
| SMA50 | $0.40 |
| SMA200 | $0.58 |
| RSI | 59.27 |
| ATR | 0.0440 |
| Shares Float | 33.47M |
| Short Float | 5.54% |
| Short Ratio | 0.95 |
| Volatility | 0.86 |
| Rel Volume | 0.14 |
Performance History
| Week | +9.87% |
| Month | +11.36% |
| Quarter | +3.16% |
| 6 Months | -35.27% |
| YTD | -40.02% |
| Year | -84.74% |
| 3 Years | -95.20% |
| 5 Years | -99.91% |
| 10 Years | -99.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.49 | 217,152 |
| 2026-06-23 | $0.49 | 1,074,000 |
| 2026-06-22 | $0.49 | 2,978,800 |
| 2026-06-18 | $0.51 | 1,977,600 |
| 2026-06-17 | $0.46 | 1,029,400 |
| 2026-06-16 | $0.45 | 1,290,100 |
| 2026-06-15 | $0.47 | 2,337,600 |
| 2026-06-12 | $0.45 | 1,432,700 |
| 2026-06-11 | $0.44 | 1,281,300 |
| 2026-06-10 | $0.41 | 549,700 |
| 2026-06-09 | $0.42 | 1,047,400 |
| 2026-06-08 | $0.43 | 1,297,100 |
| 2026-06-05 | $0.44 | 1,330,500 |
| 2026-06-04 | $0.48 | 1,650,100 |
| 2026-06-03 | $0.44 | 951,600 |
| 2026-06-02 | $0.47 | 2,189,900 |
| 2026-06-01 | $0.44 | 3,159,700 |
| 2026-05-29 | $0.48 | 3,445,800 |
| 2026-05-28 | $0.44 | 1,589,000 |
| 2026-05-27 | $0.40 | 641,300 |
| 2026-05-26 | $0.39 | 1,496,400 |
About GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
đ° Latest News
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
Benzinga âĸ 2026-06-01T11:31:13Z
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
Benzinga âĸ 2026-05-14T12:16:07Z
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-03-16T16:00:03Z
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks âĸ 2026-03-12T13:55:02Z
Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment
TheStreet âĸ 2025-12-08T21:28:30Z
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers
Benzinga âĸ 2025-10-08T12:31:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $127,000 | $0 | $213,000 | $8,000 |
| Total Expenses | $12,422,000 | $14,364,000 | $13,576,000 | $21,257,000 |
| Other Income Expense | $-15,928,000 | $800,000 | $5,412,000 | $89,000 |
| Other Non Operating Income Expenses | $11,569,000 | - | $20,000 | - |
| Net Non Operating Interest Income Expense | $-4,000 | $402,000 | $567,000 | $284,000 |
| Interest Expense Non Operating | $127,000 | $0 | $213,000 | $8,000 |
| Operating Expense | $12,422,000 | $14,364,000 | $13,576,000 | $21,257,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Net Interest Income | $-4,000 | $402,000 | $567,000 | $284,000 |
| Interest Income | $123,000 | $402,000 | $780,000 | $292,000 |
| Normalized Income | $-857,000 | $-13,962,000 | $-12,989,000 | $-20,973,000 |
| Net Income From Continuing And Discontinued Operation | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Total Operating Income As Reported | $-12,422,000 | $-14,364,000 | $-13,576,000 | $-21,257,000 |
| Net Income Common Stockholders | $-34,449,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Net Income | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Net Income Including Noncontrolling Interests | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Net Income Continuous Operations | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Pretax Income | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Special Income Charges | $-27,738,000 | $0 | $547,000 | $0 |
| Interest Income Non Operating | $123,000 | $402,000 | $780,000 | $292,000 |
| Operating Income | $-12,422,000 | $-14,364,000 | $-13,576,000 | $-21,257,000 |
| Per Share | ||||
| Diluted EPS | $-6.68 | $-6.94 | $-5.64 | $-19.46 |
| Basic EPS | $-6.68 | $-6.94 | $-5.64 | $-19.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-730,000 | $-13,962,000 | $-12,776,000 | $-20,965,000 |
| Total Unusual Items | $-27,497,000 | $800,000 | $5,392,000 | $89,000 |
| Total Unusual Items Excluding Goodwill | $-27,497,000 | $800,000 | $5,392,000 | $89,000 |
| EBITDA (Bullshit earnings) | $-28,227,000 | $-13,162,000 | $-7,384,000 | $-20,876,000 |
| EBIT | $-28,227,000 | $-13,162,000 | $-7,384,000 | $-20,876,000 |
| Diluted Average Shares | $5,513,255 | $1,897,375 | $1,347,713 | $1,072,996 |
| Basic Average Shares | $5,513,255 | $1,897,375 | $1,347,713 | $1,072,996 |
| Diluted NI Availto Com Stockholders | $-34,449,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Otherunder Preferred Stock Dividend | $5,775,000 | $0 | - | - |
| Preferred Stock Dividends | $320,000 | - | - | - |
| Other Special Charges | $27,738,000 | - | $-547,000 | - |
| Gain On Sale Of Security | $241,000 | $800,000 | $4,845,000 | $89,000 |
| Research And Development | $3,472,000 | $5,798,000 | $6,466,000 | $8,811,000 |
| Selling General And Administration | $8,950,000 | $8,566,000 | $7,110,000 | $12,446,000 |
| Other Gand A | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,787,000 | $-1,670,000 | $7,476,000 | $11,734,000 |
| Total Assets | $8,106,000 | $4,232,000 | $14,109,000 | $16,736,000 |
| Total Non Current Assets | $0 | $0 | $53,000 | $174,000 |
| Current Assets | $8,106,000 | $4,232,000 | $14,056,000 | $16,562,000 |
| Other Current Assets | $567,000 | $188,000 | $84,000 | $54,000 |
| Current Deferred Assets | $634,000 | $0 | - | - |
| Restricted Cash | $94,000 | $93,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $6,811,000 | $3,951,000 | $13,972,000 | $16,508,000 |
| Cash And Cash Equivalents | $6,811,000 | $3,951,000 | $1,079,000 | $5,672,000 |
| Non Current Prepaid Assets | - | - | $0 | $9,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | $0 | $58,000 | $174,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $64,000 |
| Current Debt And Capital Lease Obligation | - | - | $58,000 | $110,000 |
| Current Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,319,000 | $5,902,000 | $6,633,000 | $5,002,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $64,000 |
| Current Liabilities | $2,319,000 | $5,902,000 | $6,633,000 | $4,938,000 |
| Other Current Liabilities | $11,000 | $252,000 | $1,052,000 | $19,000 |
| Payables And Accrued Expenses | $2,308,000 | $5,650,000 | $5,523,000 | $4,809,000 |
| Payables | $748,000 | $3,853,000 | $4,328,000 | $3,140,000 |
| Accounts Payable | $748,000 | $3,853,000 | $4,328,000 | $3,140,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $5,786,000 | $-1,671,000 | $7,475,000 | $11,733,000 |
| Preferred Stock Equity | $1,000 | $1,000 | $1,000 | $1,000 |
| Total Equity Gross Minority Interest | $5,787,000 | $-1,670,000 | $7,476,000 | $11,734,000 |
| Stockholders Equity | $5,787,000 | $-1,670,000 | $7,476,000 | $11,734,000 |
| Retained Earnings | $-723,901,000 | $-695,227,000 | $-682,065,000 | $-674,468,000 |
| Other | ||||
| Preferred Shares Number | $121,230 | $121,230 | $121,230 | $121,230 |
| Ordinary Shares Number | $25,534,173 | $2,234,328 | $1,380,632 | $1,090,748 |
| Share Issued | $25,534,173 | $2,234,328 | $1,380,632 | $1,090,748 |
| Tangible Book Value | $5,786,000 | $-1,671,000 | $7,475,000 | $11,733,000 |
| Invested Capital | $5,786,000 | $-1,671,000 | $7,475,000 | $11,733,000 |
| Working Capital | $5,787,000 | $-1,670,000 | $7,423,000 | $11,624,000 |
| Total Capitalization | $5,787,000 | $-1,670,000 | $7,476,000 | $11,734,000 |
| Additional Paid In Capital | $729,661,000 | $693,554,000 | $689,539,000 | $686,168,000 |
| Capital Stock | $27,000 | $3,000 | $2,000 | $34,000 |
| Common Stock | $26,000 | $2,000 | $1,000 | $33,000 |
| Preferred Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Current Accrued Expenses | $1,560,000 | $1,797,000 | $1,195,000 | $1,669,000 |
| Capital Lease Obligations | - | $0 | $58,000 | $174,000 |
| Current Capital Lease Obligation | - | $0 | $58,000 | $110,000 |
| Net PPE | - | $0 | $53,000 | $165,000 |
| Gross PPE | - | $0 | $53,000 | $165,000 |
| Other Short Term Investments | - | $0 | $12,893,000 | $10,836,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $64,000 |
| Other Properties | - | - | $53,000 | $165,000 |
| Line Of Credit | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,914,000 | $-12,904,000 | $-8,852,000 | $-15,217,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,914,000 | $-12,904,000 | $-8,852,000 | $-15,217,000 |
| Cash Flow From Continuing Operating Activities | $-12,914,000 | $-12,904,000 | $-8,852,000 | $-15,217,000 |
| Operating Gains Losses | $-1,395,000 | $-800,000 | $-5,344,000 | $-150,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $12,893,000 | $-2,009,000 | $12,145,000 |
| Cash Flow From Continuing Investing Activities | $0 | $12,893,000 | $-2,009,000 | $12,145,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,508,000 | $2,976,000 | $6,268,000 | $0 |
| Financing Cash Flow | $15,775,000 | $2,976,000 | $6,268,000 | $-224,000 |
| Cash Flow From Continuing Financing Activities | $15,775,000 | $2,976,000 | $6,268,000 | $-224,000 |
| Cash Dividends Paid | $-229,000 | $0 | - | - |
| Preferred Stock Dividend Paid | $-229,000 | $0 | - | - |
| Net Preferred Stock Issuance | $10,508,000 | - | - | - |
| Preferred Stock Issuance | $10,508,000 | - | - | - |
| Net Common Stock Issuance | $0 | $2,976,000 | $6,268,000 | $-224,000 |
| Common Stock Issuance | $0 | $2,976,000 | $6,268,000 | $0 |
| Repurchase Of Capital Stock | - | - | $0 | $-224,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $213,000 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $6,905,000 | $4,044,000 | $1,079,000 | $5,672,000 |
| Beginning Cash Position | $4,044,000 | $1,079,000 | $5,672,000 | $8,968,000 |
| Changes In Cash | $2,861,000 | $2,965,000 | $-4,593,000 | $-3,296,000 |
| Proceeds From Stock Option Exercised | $5,496,000 | $0 | - | $0 |
| Net Investment Purchase And Sale | $0 | $12,893,000 | $-2,009,000 | $12,145,000 |
| Sale Of Investment | $0 | $12,893,000 | - | - |
| Change In Working Capital | $-920,000 | $828,000 | $1,937,000 | $-1,989,000 |
| Change In Other Current Liabilities | $0 | $-58,000 | $-116,000 | $-86,000 |
| Change In Other Current Assets | $0 | $53,000 | $112,000 | $95,000 |
| Change In Payables And Accrued Expense | $-1,297,000 | $937,000 | $1,962,000 | $-2,030,000 |
| Change In Prepaid Assets | $377,000 | $-104,000 | $-21,000 | $127,000 |
| Other Non Cash Items | $17,323,000 | - | $112,000 | $130,000 |
| Stock Based Compensation | $432,000 | $230,000 | $2,200,000 | $7,646,000 |
| Gain Loss On Investment Securities | $-197,000 | $-800,000 | $-4,797,000 | $-119,000 |
| Net Income From Continuing Operations | $-28,354,000 | $-13,162,000 | $-7,597,000 | $-20,884,000 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $-48,000 | $30,000 |
| Common Stock Payments | - | - | $0 | $-224,000 |
| Gain Loss On Sale Of PPE | - | - | $112,000 | $95,000 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Change In Accrued Expense | - | - | - | $0 |
| Change In Interest Payable | - | - | - | $0 |
| Change In Payable | - | - | - | $-2,030,000 |
| Change In Account Payable | - | - | - | $-2,030,000 |
| Purchase Of Investment | - | - | - | - |
Fetched: 2026-06-17